Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.
Twenty-two patients with advanced Parkinson's disease whose symptom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7-8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.